Annual report pursuant to Section 13 and 15(d)

Segment Reporting (Segments Reporting) (Details)

v3.22.2.2
Segment Reporting (Segments Reporting) (Details) - USD ($)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Nov. 01, 2021
Sep. 10, 2021
Segment Reporting Information [Line Items]        
Revenues - external customers $ 2,383,000 $ 2,371,000    
Cost of goods sold 216,000 1,462,000    
Gross profit 2,167,000 909,000    
Research and development 17,729,000 9,989,000    
General and administrative 34,128,000 22,031,000    
Operating loss (49,690,000) (31,111,000)    
Interest expense (1,412,000) (2,454,000)    
Settlement income   10,200,000    
Forgiveness of note payable and accrued interest 607,000      
Interest and other income 191,000 152,000    
Consolidated net loss (50,304,000) (23,213,000)    
Total assets 99,406,000 146,968,000    
Finance lease ROU assets 74,000 26,111,000    
Operating lease ROU assets 5,020,000   $ 1,967,000 $ 3,603,000
Fixed assets, net 36,661,000 8,628,000    
Intangible assets, net 4,851,000 952,000    
Amortization of finance lease ROU assets 599,000 1,651,000    
Depreciation of fixed assets 2,275,000 472,000    
Amortization of intangible assets 401,000 291,000    
Operating Segments [Member] | Biopharmaceuticals (iBio, Inc.) [Member]        
Segment Reporting Information [Line Items]        
Revenues - external customers 1,884,000 1,098,000    
Revenues - intersegment 1,586,000 1,017,000    
Cost of goods sold   425,000    
Gross profit 3,470,000 1,690,000    
Research and development 11,819,000 2,960,000    
General and administrative 20,844,000 13,429,000    
Operating loss (29,194,000) (14,699,000)    
Settlement income   10,200,000    
Interest and other income 184,000 151,000    
Consolidated net loss (29,010,000) (4,349,000)    
Total assets 156,893,000 175,272,000    
Operating lease ROU assets 3,068,000      
Fixed assets, net 1,373,000      
Intangible assets, net 4,851,000 952,000    
Amortization of intangible assets 401,000 291,000    
Operating Segments [Member] | Bioprocessing (iBio CDMO) [Member]        
Segment Reporting Information [Line Items]        
Revenues - external customers 499,000 1,274,000    
Revenues - intersegment 2,455,000 1,307,000    
Cost of goods sold 216,000 1,037,000    
Gross profit 2,739,000 1,543,000    
Research and development 8,260,000 8,370,000    
General and administrative 14,975,000 9,585,000    
Operating loss (20,496,000) (16,412,000)    
Interest expense (1,412,000) (2,454,000)    
Forgiveness of note payable and accrued interest 607,000      
Interest and other income 7,000 1,000    
Consolidated net loss (21,295,000) (18,864,000)    
Total assets 43,092,000 35,721,000    
Finance lease ROU assets 74,000 26,111,000    
Operating lease ROU assets 1,952,000      
Fixed assets, net 35,288,000 8,628,000    
Amortization of finance lease ROU assets 599,000 1,651,000    
Depreciation of fixed assets 2,275,000 472,000    
Eliminations [Member]        
Segment Reporting Information [Line Items]        
Revenues - intersegment (4,041,000) (2,324,000)    
Gross profit (4,041,000) (2,324,000)    
Research and development (2,350,000) (1,341,000)    
General and administrative (1,691,000) (983,000)    
Total assets $ (100,578,000) $ (64,025,000)